Wockhardt Ltd - WOCKHARDT Share Price

Sector: Pharmaceuticals | ISIN: INE049B01025
₹ 564.10 (-1.48%) icon23 Apr, 2024, 1:09:57 PM
Open
₹ 572.50
Prev. Close
₹ 572.55
Turnover(lac)
₹ 0.01
Day's High
₹ 580.30
Day's Low
₹ 560.50
52 Wk High
₹ 630.00
52 Wk Low
₹ 165.00
Book Value
₹ 126.28
Face Value
₹ 5.00
Mkt. Cap (Cr.)
₹ 8,653.35
P/E
0.00
EPS
0.00
Div. Yield
0.00

Wockhardt Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 4/23/2024 1:09:57 PM

    ₹ 564.1 -8.45 -1.48
  • Open
  • ₹ 572.5
  • Prev. Close
  • ₹ 572.55
  • Turnover(Lac.)
  • ₹ 838
  • Day's High
  • ₹ 580.3
  • Day's Low
  • ₹ 560.5
  • 52 Week's High
  • ₹ 630
  • 52 Week's Low
  • ₹ 165
  • Book Value
  • ₹ 126.28
  • Face Value
  • ₹ 5
  • Mkt Cap (₹ Cr.)
  • 8,653.35
  • P/E
  • 0
  • EPS
  • 0
  • Divi. Yield
  • 0

Wockhardt Ltd Corporate Actions

20 Mar , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

05 Feb , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

05 Feb , 2024

12:00 AM

06 Nov , 2023

12:00 AM

06 Nov , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

04 Aug , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

21 Jul , 2023

12:00 AM

AGM

Announcement date: 21 Jul , 2023

View Details

04 Aug , 2023

12:00 AM

18 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

19 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

No Record Found


Wockhardt Ltd News and Update

No Record Found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Wockhardt Ltd SHAREHOLDING SNAPSHOT
23 April , 2024 | 01:28 PM

PROMOTER - TOTAL51.60%

Indian: 51.60%

Foreign: 0%

NON-PROMOTER - TOTAL 48.40%

Institutions: 10.43%

Non-Institutions: 37.97%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Wockhardt Ltd FINANCIALS

Wockhardt Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Wockhardt Ltd

  • H F Khorakiwala
  • Executive Chairman
  • Aman Mehta
  • Independent Director
  • Murtaza H Khorakiwala
  • Managing Director
  • Huzaifa H Khorakiwala
  • Executive Director
  • Sanjaya Baru
  • Independent Director
  • D S Brar
  • Independent Director
  • Tasneem Mehta
  • Independent Director
  • Vinesh Kumar Jairath
  • Independent Director
  • Zahabiya Khorakiwala
  • Non-Exec & Non-Independent Dir
  • Akhilesh Gupta
  • Independent Director
  • Amelia Fernandes
  • Independent Director
  • Rashmi Mamtura
  • Company Sec. & Compli. Officer

Summary

Wockhardt Limited is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world. The Company is Indias leading research-based global healthcare enterprise in fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals. It has 12 manufacturing locations and there are 3 locations where research and development activities are carried out.The Company has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. It has a significant presence in USA, Europe and India, with 83% of its global revenues coming from international businesses. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified lnfectious Diseases Programme) for 5 of Anti-bacterial discovery programmes - 2 of them are Gram Negative and 3 Gram Positive effective against untreatable Superbugs. Wockhardts entire anti-infective portfolio particularly addresses the specific bacterial organism where resistances are high and breakthrough antibiotics are needed.Wockhardt Ltd was incorporated on July 8, 1999. In the year 2000, the company launched the cardiac drug enalapril maleate in the US through their marketing joint venture with Sidmak Laboratories. Also, they set up a corporate training centre with modern and state-of-the-art facility under one roof at Aurangabad. In the year 2001, the company terminated their three-year old marketing alliance with Sidmak... Read More


Reports by Wockhardt Ltd


Reports by Wockhardt Ltd

Company FAQ

No Record Found